Ocular penetration of caspofungin in a rabbit uveitis model

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 6, 2007, Pages 825-833

  Goldblum, David ^a   Fausch, Kathrin ^a   Frueh, Beatrice E ^a   Theurillat, Regula ^b   Thormann, Wolfgang ^b   Zimmerli, Stefan ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Animal model; Caspofungin; Ocular penetration; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ESCHERICHIA COLI ENDOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BLOOD EYE BARRIER; CONTROLLED STUDY; CORNEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; FUNGAL ENDOPHTHALMITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; UVEITIS; VITREOUS BODY;

ANIMALS; ANTIFUNGAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; LIPOPOLYSACCHARIDES; MALE; PEPTIDES, CYCLIC; RABBITS; TISSUE DISTRIBUTION; UVEITIS; VITREOUS BODY;

EID: 34249325130     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0460-x     Document Type: Article

References (28)

1. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46:451-457
2. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139:135-140
3. Chavez-Eng CM, Schwartz M, Constanzer ML, Matuszewski BK (1999) Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 721:229-238
4. Cornely OA, Schmitz K, Aisenbrey S (2002) The first echinocandin: caspofungin. Mycoses 45(Suppl)3:56-60
5. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142-1151
6. Durand ML, Kim IK, D'Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, Martin SS, Azar DT, Miller FS 3rd, Lujan BJ, Miller JW (2005) Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 140:552-554
7. Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ (1994) Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar d-mannitol and serum galactomannan as markers of infection. J Infect Dis 169:356-368
8. Gauthier GM, Nork TM, Prince R, Andes D (2005) Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27-e28
9. Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S (2005) Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 49:1359-1363
10. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2002) Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 46:3719-3723
11. Groll AH, Gullick BM, Petraitiene R, Petraitis V, Candelario M, Piscitelli SC, Walsh TJ (2001) Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 45:596-600
12. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent mk-0991 (L-743,872). Antimicrob Agents Chemother 41:2339-2344
13. Kulkarni PS, Mancino M (1993) Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 56:275-279
14. Levin LA, Avery R, Shore JW, Woog JJ, Baker AS (1996) The spectrum of orbital aspergillosis: A clinicopathological review. Surv Ophthalmol 41:142-154
15. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL (2005) Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49:5058-5068
16. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
17. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272-1280
18. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM (2005) Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 40:e46-e48
19. Schwartz M, Kline W, Matuszewski B (1997) Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 352:299-307
20. Srinivasan R, Kanungo R, Goyal JL (1991) Spectrum of oculomycosis in south India. Acta Ophthalmol (Copenh) 69:744-749
21. Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: Reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407-3411
22. Stevens DA, White TC, Perlin DS, Selitrennikoff CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51:173-178
23. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815-823
24. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529-1535
25. Walsh TJ, Bacher J, Pizzo PA (1988) Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467-471
26. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
27. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE (2004) Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity. J Infect Dis 190:1464-1471
28. Yohai RA, Bullock JD, Aziz AA, Markert RJ (1994) Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39:3-22